Trifarotene (Aklief)
First RAR-gamma selective retinoid for face and trunk acne with innovative efficacy-tolerability balance
이 치료에 대해
Trifarotene is a fourth-generation retinoid highly selective for the gamma (γ) subtype of nuclear retinoic acid receptor (RAR) and FDA-approved for face and trunk acne treatment (2019). Unlike conventional retinoids (tretinoin, adapalene, tazarotene) showing pan-RAR activity (α/β/γ), trifarotene is RAR-γ specific, minimizing skin irritation accompanying RAR-α activation. Consequently, it maintains high anti-acne efficacy while significantly reducing irritant side effects like erythema, desquamation, and burning sensation. With indication for both face and trunk acne, it represents a new standard in acne treatment.
작용 기전
Trifarotene binds with high selectivity to RAR-γ and activates RAR-γ gene transcription control. In acne pathophysiology, sebum overproduction, follicular keratinization abnormality, Propionibacterium acnes proliferation, and inflammation are involved. RAR-γ activation yields: ①improvement in follicular epithelial keratinization abnormality, ②sebum production suppression via sebaceous gland atrophy, ③suppression of meibomian gland hormones, ④improved follicular structure via remodeling gene expression. Meanwhile, RAR-α activation (primary RAR subtype involved in skin irritation) is minimized, substantially reducing conventional retinoid side effects (irritant dermatitis). High selectivity enables higher concentration use, improving anti-acne efficacy.
적응증
기대 효과
Inflammatory rash markedly decreases within 4-6 weeks; existing lesions improve >50% by 8-12 weeks. New lesion appearance significantly suppressed. Particularly, low irritant side effects enable better tolerability and treatment adherence.
임상 근거
위험 및 부작용
Initial worsening (initial flare) reported in ~10-20%. Erythema and desquamation seen in early stages but markedly reduced compared to conventional retinoids. Phototoxicity is low (lower than tretinoin) but sun protection recommended. Use contraindicated in pregnancy (Category C).